COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes.
COVID-19
/ epidemiology
Comorbidity
Diabetes Mellitus, Type 1
/ epidemiology
Diabetes Mellitus, Type 2
/ epidemiology
Electronic Health Records
/ statistics & numerical data
Female
Hospitalization
Humans
Hypertension
/ epidemiology
Male
Middle Aged
Odds Ratio
Prospective Studies
Severity of Illness Index
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
09
09
2020
accepted:
10
11
2020
pubmed:
4
12
2020
medline:
29
1
2021
entrez:
3
12
2020
Statut:
ppublish
Résumé
To quantify and contextualize the risk for coronavirus disease 2019 (COVID-19)-related hospitalization and illness severity in type 1 diabetes. We conducted a prospective cohort study to identify case subjects with COVID-19 across a regional health care network of 137 service locations. Using an electronic health record query, chart review, and patient contact, we identified clinical factors influencing illness severity. We identified COVID-19 in 6,138, 40, and 273 patients without diabetes and with type 1 and type 2 diabetes, respectively. Compared with not having diabetes, people with type 1 diabetes had adjusted odds ratios of 3.90 (95% CI 1.75-8.69) for hospitalization and 3.35 (95% CI 1.53-7.33) for greater illness severity, which was similar to risk in type 2 diabetes. Among patients with type 1 diabetes, glycosylated hemoglobin (HbA Diabetes status, both type 1 and type 2, independently increases the adverse impacts of COVID-19. Potentially modifiable factors (e.g., HbA
Identifiants
pubmed: 33268335
pii: dc20-2260
doi: 10.2337/dc20-2260
pmc: PMC7818316
doi:
Banques de données
figshare
['10.2337/figshare.13235066']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
526-532Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK123392
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007061
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2020 by the American Diabetes Association.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Diabetes Care. 2018 Mar;41(3):513-521
pubmed: 29330152
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Diabetes Care. 2020 Nov;43(11):e174-e177
pubmed: 32847826
Diabetes Care. 2020 Aug;43(8):e83-e85
pubmed: 32503837
Diabetes Care. 2020 Oct;43(10):e120-e122
pubmed: 32769127
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nature. 2020 Aug;584(7819):22-25
pubmed: 32760050